FRANCE; ITALY —The European Investment Bank (EIB) has extended a EUR 150 million loan to Théa to advance ophthalmic research and development and scale industrial operations across Europe, building on a EUR 50 million credit facility provided in 2021. Supported by the InvestEU guarantee framework, the transaction targets new active molecules, drug formulations, and delivery mechanisms across retinal disorders, rare inherited ocular diseases, glaucoma, and dry eye.
Founded in 1994 and headquartered in Clermont-Ferrand, France, Théa is a family-owned pharmaceutical group focused exclusively on ophthalmology, operating in more than 75 countries through 35 subsidiaries with roughly 2,500 employees. The group generated EUR 1,020 million in turnover in 2025 and directs over 12% of annual revenue toward research and innovation.
This financing matters because aging populations and chronic ocular conditions are increasing clinical demand for specialized therapies, while supply chain resilience in pharmaceuticals has become a core policy priority in Europe. Pairing laboratory R&D with domestic manufacturing infrastructure-such as Théa's industrial site in Milan-helps retain specialized scientific talent, shorten development-to-production cycles, and reduce reliance on external supply chains.
Across the pharmaceutical and biotechnology sectors, the deal underscores continued public-private risk sharing under InvestEU to de-risk long-horizon clinical development and specialized manufacturing upgrades required to meet evolving European regulatory standards. Healthcare providers, patients with underserved eye conditions, and European industrial suppliers stand to benefit as novel delivery systems and therapies progress toward commercialization.
For corporate strategists and institutional investors, the facility signals sustained institutional appetite for vertically integrated European life sciences leaders that combine consistent R&D reinvestment with regional production assets. Companies competing in ophthalmology and specialty pharma may face heightened benchmarks around supply security and localized manufacturing scale, while investors can view EU-backed debt instruments as a key mechanism financing capital-intensive European healthcare expansion.